The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee Dec. 10 recommended the approval of Pfizer, Inc.’s BNT162b2 mRNA COVID-19 vaccine. The panel voted 17-4, with one abstention, that FDA issue an emergency use authorization.

In a statement following the vote, FDA Commissioner Stephen Hahn, M.D., said the agency informed Pfizer that it will rapidly work toward finalization and issuance of an EUA, while the Centers for Disease Control and Prevention and Operation Warp Speed were concurrently notified so as to execute plans for timely vaccine distribution.

Health care workers and nursing home residents will be first in line to receive the vaccine, which is administered in two doses 21 days apart.

Related News Articles

Headline
The AHA today urged President-elect Biden to provide strong federal leadership on the COVID-19 vaccine distribution and administration process, and it pledged…
Headline
The AHA Jan. 26 at 11 a.m. ET is hosting a Q&A event covering what front-line health care workers need to know about infection prevention and the…
Headline
The Department of Health and Human Services yesterday updated its guidance to hospitals on the reporting of COVID-19-related data. HHS requests that…
Headline
The Centers for Disease Control and Prevention is tracking COVID-19 vaccinations through its COVID Data Tracker, validating the numbers with jurisdictions…
Headline
The Department of Health and Human Services yesterday released an outpatient treatment locator for monoclonal antibody therapeutics. "We know that many…
Headline
The Department of Health and Human Services and Operation Warp Speed today said they will immediately broaden the population of those eligible to be…